ArticleMicrobial cell factories2012
Myxobacteria: natural pharmaceutical factories.
Article in Microbial cell factories, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A.Molecules (Basel, Switzerland) · 2023Article
- Genomic Analysis of the Rare Slightly Halophilic Myxobacterium "Microorganisms · 2023Article
- Article
- Beyond Soil-Dwelling Actinobacteria: Fantastic Antibiotics and Where to Find Them.Antibiotics (Basel, Switzerland) · 2022Review
- Myxobacteria and their products: current trends and future perspectives in industrial applications.Folia microbiologica · 2021Review
- Biocontrol mechanism of Myxococcus fulvus B25-I-3 against Phytophthora infestans and its control efficiency on potato late blight.Folia microbiologica · 2021Article
- Eliciting the silent lucensomycin biosynthetic pathway in Streptomyces cyanogenus S136 via manipulation of the global regulatory gene adpA.Scientific reports · 2021Article
- Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.The Journal of antibiotics · 2021Review
- The Cytotoxic Natural Product Vioprolide A Targets Nucleolar Protein 14, Which Is Essential for Ribosome Biogenesis.Angewandte Chemie (International ed. in English) · 2020Article
- Characterization and structure-guided engineering of the novel versatile terpene monooxygenase CYP109Q5 from Chondromyces apiculatus DSM436.Microbial biotechnology · 2019Article
- In silico characterization of a novel putative aerotaxis chemosensory system in the myxobacterium, Corallococcus coralloides.BMC genomics · 2018Article
- The feather-degrading bacterial community in two soils as revealed by a specific primer targeting serine-type keratinolytic proteases.World journal of microbiology & biotechnology · 2016Article
- Phi Class of Glutathione S-transferase Gene Superfamily Widely Exists in Nonplant Taxonomic Groups.Evolutionary bioinformatics online · 2016Article
- AmyM, a Novel Maltohexaose-Forming α-Amylase from Corallococcus sp. strain EGB.Applied and environmental microbiology · 2015Article
- Antimalarial activity of the myxobacterial macrolide chlorotonil a.Antimicrobial agents and chemotherapy · 2014Article
- The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway.Microbial cell factories · 2014Article
- Comparative genomics of transport proteins in developmental bacteria: Myxococcus xanthus and Streptomyces coelicolor.BMC microbiology · 2013Article
- Screening of small molecules affecting mammalian P-body assembly uncovers links with diverse intracellular processes and organelle physiology.RNA biology · 2013Article
- Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay.Microbial cell factories · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxobacteria are amongst the top producers of natural products. The diversity and unique structural properties of their secondary metabolites is what make these social microbes highly attractive for drug discovery. Screening of products derived from these bacteria has revealed a puzzling amount of hits against infectious and non-infectious human diseases. Preying mainly on other bacteria and fungi, why would these ancient hunters manufacture compounds beneficial for us? The answer may be the targeting of shared processes and structural features conserved throughout evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.